News
DGAP-Adhoc: Ad hoc: MorphoSys AG startet Angebot von Wandelschuldverschreibungen in Höhe von etwa EUR 325 Mio.
DGAP-Adhoc: Ad hoc: MorphoSys AG startet Angebot von Wandelschuldverschreibungen in Höhe von etwa EUR 325 Mio.
DGAP-Adhoc: Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds
DGAP-Adhoc: Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds
![EQS-News: NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
EQS-News: NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
![EQS-News: NeuroRx und Relief veröffentlichen Topline-Wirksamkeitsdaten von Patienten, die im US-FDA-Härtefallprogramm ('Expanded Access Protocol') zur Behandlung von COVID-19 bedingtem akutem Lungenversagen mit RLF-100(TM) (Aviptadil) behandelt wurde](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-News: NeuroRx und Relief veröffentlichen Topline-Wirksamkeitsdaten von Patienten, die im US-FDA-Härtefallprogramm ('Expanded Access Protocol') zur Behandlung von COVID-19 bedingtem akutem Lungenversagen mit RLF-100(TM) (Aviptadil) behandelt wurde
EQS-News: NeuroRx und Relief veröffentlichen Topline-Wirksamkeitsdaten von Patienten, die im US-FDA-Härtefallprogramm ('Expanded Access Protocol') zur Behandlung von COVID-19 bedingtem akutem Lungenversagen mit RLF-100(TM) (Aviptadil) behandelt wurde
![DGAP-News: Formycon erhält Fördermittel für COVID-19-Arzneimittelforschung von der Bayerischen Forschungsstiftung](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: Formycon erhält Fördermittel für COVID-19-Arzneimittelforschung von der Bayerischen Forschungsstiftung
DGAP-News: Formycon erhält Fördermittel für COVID-19-Arzneimittelforschung von der Bayerischen Forschungsstiftung
![DGAP-News: Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
DGAP-News: Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
![DGAP-News: MUBADALA INVESTMENT COMPANY AND NOVO HOLDINGS A/S INVEST € 250 M IN EVOTEC SE: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: MUBADALA INVESTMENT COMPANY AND NOVO HOLDINGS A/S INVEST € 250 M IN EVOTEC SE
DGAP-News: MUBADALA INVESTMENT COMPANY AND NOVO HOLDINGS A/S INVEST € 250 M IN EVOTEC SE
![DGAP-Adhoc: Mubadala Investment Company und Novo Holdings A/S investieren 250 Mio. € in Evotec SE: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-Adhoc: Mubadala Investment Company und Novo Holdings A/S investieren 250 Mio. € in Evotec SE
DGAP-Adhoc: Mubadala Investment Company und Novo Holdings A/S investieren 250 Mio. € in Evotec SE
![DGAP-Adhoc: Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-Adhoc: Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
DGAP-Adhoc: Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
![DGAP-News: NanoRepro AG: Covid19-Antigentest - Die Auslieferung läuft bereits](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: NanoRepro AG: Covid19-Antigentest - Die Auslieferung läuft bereits
DGAP-News: NanoRepro AG: Covid19-Antigentest - Die Auslieferung läuft bereits
![DGAP-News: Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
DGAP-News: Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
![DGAP-News: Strategischer Investor Active Ownership Gruppe zeichnet Barkapitalerhöhung in Höhe von 25,75 Mio. Euro](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-News: Strategischer Investor Active Ownership Gruppe zeichnet Barkapitalerhöhung in Höhe von 25,75 Mio. Euro
DGAP-News: Strategischer Investor Active Ownership Gruppe zeichnet Barkapitalerhöhung in Höhe von 25,75 Mio. Euro
![DGAP-Adhoc: Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-Adhoc: Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
DGAP-Adhoc: Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
![DGAP-Adhoc: Formycon platziert Barkapitalerhöhung in Höhe von 25,75 Millionen Euro bei strategischem Investor](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-Adhoc: Formycon platziert Barkapitalerhöhung in Höhe von 25,75 Millionen Euro bei strategischem Investor
DGAP-Adhoc: Formycon platziert Barkapitalerhöhung in Höhe von 25,75 Millionen Euro bei strategischem Investor
![DGAP-News: EVOTEC ACHIEVES MILESTONE IN ITS NEURODEGENERATION COLLABORATION WITH BRISTOL MYERS SQUIBB: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC ACHIEVES MILESTONE IN ITS NEURODEGENERATION COLLABORATION WITH BRISTOL MYERS SQUIBB
DGAP-News: EVOTEC ACHIEVES MILESTONE IN ITS NEURODEGENERATION COLLABORATION WITH BRISTOL MYERS SQUIBB
![DGAP-News: EVOTEC ERREICHT MEILENSTEIN IN NEUROLOGIE-KOOPERATION MIT BRISTOL MYERS SQUIBB: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC ERREICHT MEILENSTEIN IN NEUROLOGIE-KOOPERATION MIT BRISTOL MYERS SQUIBB
DGAP-News: EVOTEC ERREICHT MEILENSTEIN IN NEUROLOGIE-KOOPERATION MIT BRISTOL MYERS SQUIBB
![DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2020
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2020
![DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2020](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2020
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2020
![EQS-News: Relief Therapeutics ernennt Industrie-Veteran Jack Weinstein zum Chief Financial Officer und Treasurer](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EQS-News: Relief Therapeutics ernennt Industrie-Veteran Jack Weinstein zum Chief Financial Officer und Treasurer
EQS-News: Relief Therapeutics ernennt Industrie-Veteran Jack Weinstein zum Chief Financial Officer und Treasurer
![EQS-News: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EQS-News: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
EQS-News: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
![Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
![DGAP-News: PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-News: PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.
DGAP-News: PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.
![DGAP-News: PAION BERICHTET ÜBER FORTSCHRITTE MIT BYFAVO (REMIMAZOLAM) BEI SEINEM LIZENZNEHMER ACACIA IN DEN USA](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: PAION BERICHTET ÜBER FORTSCHRITTE MIT BYFAVO (REMIMAZOLAM) BEI SEINEM LIZENZNEHMER ACACIA IN DEN USA
DGAP-News: PAION BERICHTET ÜBER FORTSCHRITTE MIT BYFAVO (REMIMAZOLAM) BEI SEINEM LIZENZNEHMER ACACIA IN DEN USA
DGAP-News: Biotest AG: Biotest behandelt ersten COVID-19 Patienten mit Trimodulin
DGAP-News: Biotest AG: Biotest behandelt ersten COVID-19 Patienten mit Trimodulin
DGAP-News: Biotest AG: Biotest treats first COVID-19 patient with trimodulin
DGAP-News: Biotest AG: Biotest treats first COVID-19 patient with trimodulin